EU regulator green-lights first injectable HIV drug


EU regulator green-lights first injectable HIV drug

Sunday, October 18, 2020

Print this page Email A Friend!

THE HAGUE, Netherlands (AFP) — The EU's medicines regulator last Friday gave the green light for the first injectable treatment for HIV, the virus that causes AIDS, which could change the lives of millions of people.

The cocktail of two antiretroviral (ARV) drugs, rilpivirine and cabotegravir, can be given every few months instead of a daily pill to keep HIV infection under control.

“The two medicines are the first ARVs that come in a long-acting injectable formulation,” the European Medicines Agency (EMA) said in a statement.

“This means that instead of daily pills, patients receive intramuscular injections monthly or every two months,” the Amsterdam-based agency said.

The EMA's recommendation for marketing authorisation must now be approved by the European Commission before it can be prescribed across the 27-nation bloc.

The injectable version of the drugs could be transformative for people with HIV.

People who forget to take their daily, lifelong doses of HIV medication run the risk of the virus rebounding to make them ill.

They can also develop resistance to the drugs they are using — which would require a more expensive replacement.

The new cocktail of rilpivirine and cabotegravir — branded as Rekambys and Vocabria — work together “to block the ability of the virus to replicate”, the EMA said.

The agency said the injectable treatment is a “significant reducing the burden associated with daily pill-taking”.

Around 38 million people around the world were living with HIV in 2019, according to World Health Organization figures, with some 2.3 million people in Europe.

There is no cure for the HIV infection, but ARV therapies can control the virus, help prevent transmission and allow patients to live longer.

Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at




1. We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper � email addresses will not be published.

2. Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.

3. We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.

4. Please do not write in block capitals since this makes your comment hard to read.

5. Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed:

6. If readers wish to report offensive comments, suggest a correction or share a story then please email:

7. Lastly, read our Terms and Conditions and Privacy Policy

comments powered by Disqus



Today's Cartoon

Click image to view full size editorial cartoon